A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

Project: Other project

Project Details

StatusActive
Effective start/end date11/12/2111/11/26